• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Biofrontera Ag claimed ownership of 8,000,000 shares

    10/28/21 9:46:54 PM ET
    $BFRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Biofrontera AG

    (Last) (First) (Middle)
    HEMMELRATHER WEG 201

    (Street)
    LEVERKUSEN, GERMANY 2M D-51377

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/28/2021
    3. Issuer Name and Ticker or Trading Symbol
    Biofrontera Inc. [ BFRI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 8,000,000 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Hermann Luebbert as Chief Executive Officer of Biofrontera AG 10/28/2021
    /s/ Ludwig Lutter as Chief Financial Officer of Biofrontera AG 10/28/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BFRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      2/25/22 4:01:31 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      12/21/21 4:01:09 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      11/29/21 4:01:24 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

      Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the "Company") (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, decided today its American Depositary Shares ("ADS") should be delisted from the Nasdaq Capital Market ("Nasdaq") and its reporting obligations with the Securities and Exchange Commission ("SEC") should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the

      2/14/22 2:05:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG announces mediation results

      Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (OTC:BFFTF) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021

      11/19/21 8:45:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Biofrontera AG

      EFFECT - Biofrontera AG (0001712641) (Filer)

      3/14/22 12:15:06 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15F-12B filed by Biofrontera AG

      15F-12B - Biofrontera AG (0001712641) (Filer)

      3/9/22 4:27:42 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Biofrontera AG

      POS AM - Biofrontera AG (0001712641) (Filer)

      3/9/22 2:35:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Financials

    Live finance-specific insights

    See more
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

      Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:00 am ET)Dial-in number Germany: +49 69201744220Conference code: 35058739# In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference co

      11/9/21 5:45:49 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

      Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 63828444# In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 78540812# Plea

      8/12/21 8:55:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Biofrontera Ag claimed ownership of 8,000,000 shares

      3 - Biofrontera AG (0001712641) (Reporting)

      10/28/21 9:46:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care